Takeda Pharmaceuticals – iF! - Inovativna farmaceutska inicijativa

About Us

Association

Mission and Vision

Strategy and Objectives

Organisational Structure

Statute of the Innovative Pharmaceutical Initiative

Business Ethics

Code of Conduct of Innovative Pharmaceutical Companies

Public Disclosures

iF! Members Disclosures

Financial reports

Frequently Asked Questions

Strategic Projects

HeMED

Serialization of medicines / NMVO

Clinical practice guidelines and monitoring treatment outcomes

Initiatives

WeWontRest

Treatment Outcomes 2020/30

Clinical trials

Useful Links

Useful links list

Source of information on vaccines and vaccination

Members

News

02/2021

Advances were preceded by many failures

Advances in the research and development of therapeutic options witnessed in recent years...

02/2021

Treatment Outcomes

There are significant differences in treatment outcomes across European Union member states, and...

02/2021

The treatment of hematologic malignant diseases in Croatia has significantly improved

Thanks to new knowledge and the discovery of new medicines that had previously...

Innovative Pharmaceutical Initiative – iF!

Florijana Andrašeca 20, 10000 Zagreb, Croatia

+385 1 2020 434

19

innovative pharmaceutical companies

703

employees

56

% of the Croatian medicines market

32

M Eur of transferred value in 2024

30

years of the Association’s activity

Homepage

> Members

> Takeda Pharmaceuticals

Company title

Takeda Pharmaceuticals

/ Takeda Pharmaceuticals Croatia d.o.o.

Headquarters

Takeda Pharmaceutical Company Ltd., Tokyo, Japan

Croatia office headquarters

Zagreb, Ivana Lučića 2a, 10000 Zagreb

Croatia office contact

Croatia number of employees

24

Therapeutic areas

–

Gastroenterology

–

Haematology

–

Rare diseases

–

Oncology

–

Transplantation

–

Plasma therapies

Company claim

"Better health for people, brighter future for the world."

Company URL

Members

19

innovative pharmaceutical companies

703

employees

56

% of the Croatian medicines market

32

M Eur of transferred value in 2024

30

years of the Association’s activity